However, additional studies are required to assess whether MPO inhibitors could suppress the production of pathogenic auto-antibodies similar to that observed with PAD inhibitors in models of lupus [198], collagen-induced arthritis [159], and colitis [199]. Here, MPO is linked to systemic lupus erythematosus.